January 31, 2018
Sanofi asks EMA to review drug for sleeping sickness
Sanofi has asked the European Medicines Agency (EMA) to review fexinidazole for the treatment of sleeping sickness. Fexinidazole is being…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
January 31, 2018
Boehringer Ingelheim appoints new CEO
Boehringer Ingelheim has appointed new CEO Wednesday, who will replace Paul Fonteyne, as he will retire after 15 years, on December…
January 31, 2018
Nuformix wraps up pilot study for its NXP002 for treating fibrosis
Nuformix has completed pilot pre-clinical studies that further validate the potential for its NXP002 programme in successfully and safely treating…
January 30, 2018
Romastru brings Amryt’s cholesterol treatment Lojuxta to Romania and Bulgaria
Amryt has signed an exclusive distribution agreement for Lojuxta (lomitapide) covering Romania and Bulgaria with Romastru Trading SRL (Romastru), a…
January 30, 2018
Beximco increases profit in Q2 2017
The London-listed Bangladesh-based pharmaceutical company, Beximco, has had net sales in the second quarter increased 12.8% to BDT 4,359.9m /…
January 30, 2018
AB Biosciences, Shire in licence deal
AB Biosciences will grant Shire an exclusive worldwide license to develop and commercialize AB Biosciences’ pan receptor interacting molecule (PRIM)…
January 29, 2018
Sanofi buys Ablynx for €3,9 billion
Sanofi will buy Belgian Nanobody technology specialist Ablynx for €3.9 billion, it was announced Monday by both companies.
January 29, 2018
Bormioli Pharma packaging innovations finds solution to unstable drug formulations
This year’s Pharmapack Conference sees Bormioli Pharma, one of the world’s leading glass and plastic packaging manufacturers for the pharmaceutical sector, make a…
January 29, 2018
Faron’s Traumakine on Fast Track, as the US FDA says it’s good to go
Faron Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for Traumakine, which also has…
January 26, 2018
EMA confirms negative stand for Santhera’s Raxone extension application in Duchene
Santhera Pharmaceuticals will still remain without extension application for Raxone in Duchenne muscular dystrophy (DMD) in Europe, as expected. The…